Living cells engineered to fight disease have transformed some blood cancers and are being pushed toward solid tumors, autoimmunity, and off-the-shelf manufacturing.

Sources: [1][2]

Evidence standingClinical practice
Key facts
Portal
Future Pharma
Stage
Clinical practice in defined indications
Evidence
Clinical practice
Reversible
Difficult to reverse
Reviewed
Jun 2026
Read time
8 min
Contents

Page status

Manufacturing cost and speed · Serious immune toxicities

Key takeaways

  • CAR-TTermCAR-TA therapy using a patient's T cells engineered to recognize and attack cancer, a living-cell treatment.In glossary → therapies produce durable remissions in some blood cancers that resisted other treatment.
  • Solid tumors and autoimmune disease are the expansion fronts, with early autoimmune results notable.
  • Cost, manufacturing, and serious immune toxicities constrain access and scale.

How engineered cells work

In CAR-TTermCAR-TA therapy using a patient's T cells engineered to recognize and attack cancer, a living-cell treatment.In glossary → therapy, a patient's T cells are collected, engineered to express a receptor that recognizes a cancer marker, expanded, and reinfused. The living drug then proliferates and persists, attacking cells carrying the target.

The same logic extends to other cell types and targets: engineered T cells against autoimmune B cells, natural killer cells, and stem-cell-derived products intended to be manufactured in advance rather than made per patient.

Frontier and constraints

The frontier is beyond blood cancer: durable responses in refractory autoimmune disease have drawn intense interest, and solid-tumor programs are working against a hostile tumor environment and antigen escape.

The constraints are practical. Bespoke manufacturing is slow and expensive, toxicities such as cytokine release require specialized centers, and off-the-shelf allogeneic products must solve rejection and persistence. Scaling access is as much a manufacturing problem as a biology problem.

Open questions

  • Can allogeneic 'off-the-shelf' products match bespoke cells on durability?
  • Will cell therapy work against common solid tumors, not just blood cancers?

Watchlist

Signals that would move this entry along the evidence scale.

Autoimmune indicationsAllogeneic manufacturingSolid-tumor strategies

Key terms

References

  1. FDA approval of first CAR-T therapy (Kymriah). U.S. FDA, 2017
    First approved CAR-T cell therapy in the United States.
  2. CAR-T in refractory autoimmune disease. Müller et al., NEJM, 2024
    Reported durable responses in severe autoimmune disease.

Cite this page

Future Human Atlas. “Engineered Cell Therapies.” Last reviewed Jun 2026. https://future-human-wiki.vercel.app/articles/cell-therapies

Suggest an edit